AU2011311516B2 - Phosphospecific antibodies recognising Tau - Google Patents

Phosphospecific antibodies recognising Tau Download PDF

Info

Publication number
AU2011311516B2
AU2011311516B2 AU2011311516A AU2011311516A AU2011311516B2 AU 2011311516 B2 AU2011311516 B2 AU 2011311516B2 AU 2011311516 A AU2011311516 A AU 2011311516A AU 2011311516 A AU2011311516 A AU 2011311516A AU 2011311516 B2 AU2011311516 B2 AU 2011311516B2
Authority
AU
Australia
Prior art keywords
seq
amino acid
antibody
acid sequence
tau
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011311516A
Other languages
English (en)
Other versions
AU2011311516A1 (en
Inventor
Oskar Adolfsson
Andreas Muhs
Andrea Pfeifer
Maria Pihlgren
Fred Van Leuven
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KU Leuven
AC Immune SA
Original Assignee
KU Leuven
AC Immune SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44947048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2011311516(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by KU Leuven, AC Immune SA filed Critical KU Leuven
Priority to AU2013205313A priority Critical patent/AU2013205313B2/en
Publication of AU2011311516A1 publication Critical patent/AU2011311516A1/en
Application granted granted Critical
Publication of AU2011311516B2 publication Critical patent/AU2011311516B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AU2011311516A 2010-10-07 2011-10-07 Phosphospecific antibodies recognising Tau Ceased AU2011311516B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013205313A AU2013205313B2 (en) 2010-10-07 2013-04-11 Phosphospecific antibodies recognising tau

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10186810 2010-10-07
EP10186810.7 2010-10-07
EP11174248.2 2011-07-15
EP11174248 2011-07-15
PCT/EP2011/067604 WO2012045882A2 (en) 2010-10-07 2011-10-07 Pharmaceutical composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013205313A Division AU2013205313B2 (en) 2010-10-07 2013-04-11 Phosphospecific antibodies recognising tau

Publications (2)

Publication Number Publication Date
AU2011311516A1 AU2011311516A1 (en) 2013-04-18
AU2011311516B2 true AU2011311516B2 (en) 2015-06-11

Family

ID=44947048

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011311516A Ceased AU2011311516B2 (en) 2010-10-07 2011-10-07 Phosphospecific antibodies recognising Tau

Country Status (29)

Country Link
US (2) US9304138B2 (enExample)
EP (2) EP2987807A3 (enExample)
JP (2) JP6371526B2 (enExample)
KR (1) KR101988672B1 (enExample)
CN (1) CN103502272B (enExample)
AR (1) AR085198A1 (enExample)
AU (1) AU2011311516B2 (enExample)
BR (1) BR112013008333B1 (enExample)
CA (1) CA2812865C (enExample)
CL (1) CL2013000951A1 (enExample)
CO (1) CO6710903A2 (enExample)
CR (1) CR20130160A (enExample)
DK (1) DK2625198T3 (enExample)
EC (1) ECSP13012609A (enExample)
ES (1) ES2548686T3 (enExample)
HK (1) HK1216897A1 (enExample)
HU (1) HUE027649T2 (enExample)
IL (1) IL225568A (enExample)
MX (1) MX338421B (enExample)
MY (1) MY164376A (enExample)
PE (1) PE20140218A1 (enExample)
PH (1) PH12013500615A1 (enExample)
PL (1) PL2625198T3 (enExample)
RU (1) RU2603078C2 (enExample)
SG (1) SG189136A1 (enExample)
SI (1) SI2625198T1 (enExample)
TW (1) TW201216985A (enExample)
WO (1) WO2012045882A2 (enExample)
ZA (1) ZA201302432B (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10266585B2 (en) * 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
WO2012045882A2 (en) * 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition
LT2627672T (lt) 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Žmogaus antikūnai prieš tau baltymą
WO2012106363A2 (en) * 2011-01-31 2012-08-09 Intellect Neurosciences Inc. Treatment of tauopathies
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
JP6358953B2 (ja) 2011-10-07 2018-07-18 エーシー イミューン エス．エー． タウを認識するホスホ特異的抗体
CA2859665C (en) 2011-12-20 2024-05-21 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
CA2869438C (en) * 2012-04-05 2021-08-17 Ac Immune S.A. Humanized tau antibody
EP2870176A4 (en) * 2012-07-03 2016-09-28 Univ Washington ANTIBODIES DIRECTED AGAINST TAU
WO2014016737A1 (en) * 2012-07-24 2014-01-30 Pfizer Inc. Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
EP2885010B1 (en) * 2012-08-16 2020-01-01 Ipierian, Inc. Methods of treating a tauopathy
US12024568B2 (en) 2012-09-13 2024-07-02 Cornell University Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
JP6284548B2 (ja) 2012-12-21 2018-02-28 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ヒト抗タウ抗体
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
MX374811B (es) 2013-03-15 2025-03-06 Ac Immune Sa Anticuerpos anti-tau y métodos de uso.
EP3003390B1 (en) 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
GB201312226D0 (en) * 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
BR112016010454A2 (pt) * 2013-11-27 2017-12-05 Ipierian Inc métodos para tratar uma taupatia
CR20160270A (es) 2013-12-20 2016-09-05 Hoffmann La Roche ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽，抗Tau抗体，及其使用方法
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
BR112017006419A2 (pt) 2014-09-30 2017-12-19 Univ Washington medições cinéticas de tau
EP3221349B1 (en) * 2014-11-19 2020-11-04 Axon Neuroscience SE Humanized tau antibodies in alzheimer's disease
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
AR103713A1 (es) 2015-02-26 2017-05-31 Lilly Co Eli Anticuerpos contra tau y sus usos
NZ775762A (en) 2015-06-05 2025-02-28 Genentech Inc Anti-tau antibodies and methods of use
ES2809728T3 (es) 2015-06-24 2021-03-05 Hoffmann La Roche Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
SG10202010735PA (en) 2015-07-06 2020-11-27 UCB Biopharma SRL Tau-binding antibodies
JO3711B1 (ar) * 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
PT3334761T (pt) * 2015-08-13 2023-08-17 Univ New York Moléculas baseadas em anticorpo seletivo para o epítopo {p}ser404 da tau e os seus usos no diagnóstico e tratamento de tauopatias
JP2019510481A (ja) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
JP7029415B2 (ja) 2016-07-12 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 過リン酸化タウに特異的な抗体およびその使用方法
JP6949102B2 (ja) 2016-08-09 2021-10-13 イーライ リリー アンド カンパニー 併用療法
EP3551220B1 (en) * 2016-12-07 2025-01-29 Genentech, Inc. Anti-tau antibodies and methods of use
EP3551655A2 (en) 2016-12-07 2019-10-16 Genentech, Inc. Anti-tau antibodies and methods of their use
US10995137B2 (en) 2017-01-04 2021-05-04 H. Lundbeck A/S Antibodies specific for hyperphosphorlated tau for the treatment of ocular diseases
CA3053379A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
JP2018139530A (ja) * 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
EA039569B1 (ru) * 2017-03-14 2022-02-11 Х. Лундбекк А/С Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
TWI771389B (zh) 2017-03-16 2022-07-21 美商健生生物科技公司 抗phf-tau抗體及其用途
WO2018217630A1 (en) * 2017-05-21 2018-11-29 University Of Tennessee Research Foundation Methods and compositions for targeting tissue lesions
JP6851549B2 (ja) 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
JP7267606B2 (ja) * 2017-11-28 2023-05-02 国立大学法人三重大学 検出方法
TW201946654A (zh) 2018-03-05 2019-12-16 比利時商健生藥品公司 抗ＰＨＦ－Ｔａｕ抗體及其用途
EP3829634A1 (en) 2018-07-31 2021-06-09 Eli Lilly and Company Combination therapy
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
US12116415B2 (en) * 2018-10-09 2024-10-15 Single Cell Technology, Inc. Anti-BCMA antibodies
WO2020077380A1 (en) * 2018-10-17 2020-04-23 The University Of Queensland Methods and compositions for treating tauopathies
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
EP3906055A4 (en) * 2019-01-04 2023-01-04 Trio Pharmaceuticals, Inc. MULTISPECIFIC PROTEIN MOLECULES AND THEIR USES
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CN113874078B (zh) 2019-04-05 2025-05-06 Tauc3生物制品有限公司 抗tauc3抗体及其应用
BR112021017046A2 (pt) * 2019-04-12 2021-11-09 Phanes Therapeutics Inc Receptores de antígeno quiméricos antirreceptores de folato 1 humanizados e seus usos
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
CN110028583B (zh) * 2019-05-07 2020-09-11 温州医科大学 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
CN112752251B (zh) * 2019-10-29 2022-05-06 中国移动通信有限公司研究院 一种ue标识符的分配方法、装置和计算机可读存储介质
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
AU2021217290A1 (en) * 2020-02-05 2022-07-21 Sumitomo Pharma Co., Ltd. Determination agent and determination method for tauopathy and dementia-related diseases
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
CN116723856A (zh) 2020-06-25 2023-09-08 默沙东有限责任公司 靶向丝氨酸413处磷酸化的tau的高亲和力抗体
KR20230157296A (ko) * 2020-12-16 2023-11-16 보이저 테라퓨틱스, 인크. 타우 결합 화합물
EP4014997A1 (en) 2020-12-16 2022-06-22 Consejo Superior de Investigaciones Científicas (CSIC) Stard1 inhibitors for the treatment of lysosomal disorders
US20250276076A1 (en) * 2021-03-18 2025-09-04 Seagen Inc. Anti-alpp/alppl2 antibodies and antibody-drug conjugates
CL2021001380A1 (es) 2021-05-26 2022-01-14 Corporacion Centro Int De Biomedicina Icc Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias.
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
JP2025535203A (ja) 2022-09-15 2025-10-23 ボイジャー セラピューティクス インコーポレイテッド タウ結合化合物
EP4658689A2 (en) * 2023-02-02 2025-12-10 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Phosphomimetic mutants, phosphospecific antibodies, and uses thereof
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025128975A1 (en) * 2023-12-14 2025-06-19 Immunitas Therapeutics, Inc. Cd161 binding proteins and related methods
WO2025134068A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Antibody drug conjugates targeting proteinopathies, and uses thereof
WO2026102093A1 (en) 2024-11-07 2026-05-15 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
US20020086009A1 (en) * 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
US20050221391A1 (en) * 2000-07-11 2005-10-06 Peter Davies Reagents and methods for identification of binding agents
US20080050383A1 (en) * 2006-03-29 2008-02-28 New York University Immunotherapy for clearing pathological tau conformers
EP2210901A1 (en) * 2007-10-19 2010-07-28 Immunas Pharma, Inc. Antibody capable of specifically binding to a oligomer, and use thereof
WO2010106127A2 (en) * 2009-03-18 2010-09-23 Ac Immune S.A. Method for therapeutic use
WO2010115843A2 (en) * 2009-04-03 2010-10-14 Ac Immune S.A. Pharmaceutical composition
WO2010144711A2 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
WO2011013034A1 (en) * 2009-07-30 2011-02-03 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
WO1993011231A1 (en) 1991-12-06 1993-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
AU677216B2 (en) 1992-07-27 1997-04-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Targeting of liposomes to the blood-brain barrier
DE69526973T3 (de) 1994-10-21 2010-01-07 Innogenetics N.V. Sequenzen von hepatitis-c-virus genotype 7, und deren verwendung als vorbeugende, therapeutische und diagnostische mittel
US5756662A (en) 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
AU2001286930A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
CA2450073C (en) 2001-07-25 2017-08-29 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
JP4995423B2 (ja) 2002-12-03 2012-08-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア
KR20050101537A (ko) 2002-12-24 2005-10-24 뉴로켐 (인터내셔널) 리미티드 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제
WO2005025511A2 (en) 2003-09-10 2005-03-24 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
US7238788B2 (en) 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
KR20070094890A (ko) * 2004-10-25 2007-09-27 머크 앤드 캄파니 인코포레이티드 안티 ａｄｄｌ 항체 및 그 용도
US20080220449A1 (en) * 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
CA2692039C (en) 2007-06-13 2019-07-02 Research Development Foundation Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling
WO2012045882A2 (en) * 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086009A1 (en) * 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
US20050221391A1 (en) * 2000-07-11 2005-10-06 Peter Davies Reagents and methods for identification of binding agents
US20080050383A1 (en) * 2006-03-29 2008-02-28 New York University Immunotherapy for clearing pathological tau conformers
EP2210901A1 (en) * 2007-10-19 2010-07-28 Immunas Pharma, Inc. Antibody capable of specifically binding to a oligomer, and use thereof
WO2010106127A2 (en) * 2009-03-18 2010-09-23 Ac Immune S.A. Method for therapeutic use
WO2010115843A2 (en) * 2009-04-03 2010-10-14 Ac Immune S.A. Pharmaceutical composition
WO2010144711A2 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
WO2011013034A1 (en) * 2009-07-30 2011-02-03 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BHASKAR K. et al., NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 1 October 2010, vol. 36, no. 6, pages 462-477 *
HOFFMANN R. et al., BIOCHEMISTRY, 1997, vol. 36, no. 26, pages 8114-8124 *
JICHA G.A. et al. JOURNAL OF NEUROSCIENCE, 1999, vol. 19, no. 17, pages 7486-7494 *
LEE G. et al., JOURNAL OF NEUROSCIENCE, 2004, vol. 24, no. 9, pages 2304-2312 *
LICHTENBERG-KRAAG B. et al., PNAS, 1992, vol. 89, no. 12, pages 5384-5388 *
OTVOS L. et al., JOURNAL OF NEUROSCIENCE RESEARCH, 1994, vol. 39, pages 669-673 *
RODER H. M. et al., JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, vol. 272, no. 7, pages 4509-4515 *
SINGER D. et al., ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2009, vol. 395, no. 7, pages 2263-2267 *
SINGER D. et al., INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS, 2005, vol. 11, no. 4, pages 279-289 *
TORREILLES F. et al., MOLECULAR BRAIN RESEARCH, 2000, vol. 78, pages 181-185 *
ZEMLAN F. P. et al., JOURNAL OF NEUROSCIENCE RESEARCH, 1996, vol. 46, no. 1, pages 90-97 *
ZHENG-FISCHHOEFER Q. et al., EUROPEAN JOURNAL OF BIOCHEMISTRY, 1998, vol. 252, no. 3, pages 542-552 *

Also Published As

Publication number Publication date
AU2011311516A1 (en) 2013-04-18
EP2625198A2 (en) 2013-08-14
KR101988672B1 (ko) 2019-06-12
CR20130160A (es) 2013-09-03
RU2603078C2 (ru) 2016-11-20
US10100104B2 (en) 2018-10-16
MX338421B (es) 2016-04-15
BR112013008333B1 (pt) 2022-10-11
JP6371526B2 (ja) 2018-08-08
US9304138B2 (en) 2016-04-05
CN103502272A (zh) 2014-01-08
RU2013120544A (ru) 2014-11-20
EP2625198B1 (en) 2015-07-22
CL2013000951A1 (es) 2014-01-03
AR085198A1 (es) 2013-09-18
EP2987807A2 (en) 2016-02-24
US20120276009A1 (en) 2012-11-01
TW201216985A (en) 2012-05-01
WO2012045882A2 (en) 2012-04-12
US20160304590A1 (en) 2016-10-20
CA2812865A1 (en) 2012-04-12
DK2625198T3 (en) 2015-09-28
SG189136A1 (en) 2013-05-31
PE20140218A1 (es) 2014-03-01
BR112013008333A2 (pt) 2021-09-21
HK1187928A1 (zh) 2014-04-17
HUE027649T2 (en) 2016-10-28
HK1216897A1 (en) 2016-12-09
PL2625198T3 (pl) 2015-12-31
ECSP13012609A (es) 2013-07-31
CO6710903A2 (es) 2013-07-15
ES2548686T3 (es) 2015-10-20
SI2625198T1 (sl) 2015-11-30
WO2012045882A3 (en) 2012-05-31
IL225568A0 (en) 2013-06-27
CA2812865C (en) 2021-01-26
KR20130115279A (ko) 2013-10-21
IL225568A (en) 2017-06-29
JP2014502141A (ja) 2014-01-30
MY164376A (en) 2017-12-15
CN103502272B (zh) 2016-06-15
JP2017113004A (ja) 2017-06-29
PH12013500615A1 (en) 2013-06-03
EP2987807A3 (en) 2016-06-01
MX2013003800A (es) 2013-06-28
ZA201302432B (en) 2016-07-27

Similar Documents

Publication Publication Date Title
US10100104B2 (en) Methods of diagnosing tau-protein-associated disease
EP2764022B9 (en) Phosphospecific antibodies recognising tau
EP2834270B1 (en) Humanized tau antibody
AU2013205313B2 (en) Phosphospecific antibodies recognising tau
AU2016202289A1 (en) Phosphospecific antibodies recognising tau
HK1187928B (en) Antibodies recognising phospho-tau
HK1200469B (en) Phosphospecific antibodies recognising tau

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired